Patents by Inventor Gregory L. Moore

Gregory L. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20120156207
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 10, 2011
    Publication date: June 21, 2012
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20120148578
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: November 21, 2011
    Publication date: June 14, 2012
    Applicant: XENCOR, INC.
    Inventors: SEUNG YUP CHU, JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR, GREGORY L. MOORE, IGOR VOSTIAR
  • Methods and compositions for inhibiting CD32B expressing cells
    Patent number: 8063187
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: November 22, 2011
    Assignee: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY
    Publication number: 20110236375
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Application
    Filed: January 19, 2011
    Publication date: September 29, 2011
    Applicant: XENCOR, INC.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
    Publication number: 20110189178
    Abstract: The present application relates to therapeutic moieties displaying reduced immunogen response, particularly for therapeutic purposes.
    Type: Application
    Filed: February 4, 2011
    Publication date: August 4, 2011
    Applicant: XENCOR, INC.
    Inventors: John Desjarlais, Gregory L. Moore, Holly M. Horton
  • COMPOSITIONS AND METHODS FOR SIMULTANEOUS BIVALENT AND MONOVALENT CO-ENGAGEMENT OF ANTIGENS
    Publication number: 20110054151
    Abstract: Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.
    Type: Application
    Filed: September 2, 2010
    Publication date: March 3, 2011
    Applicant: Xencor, Inc.
    Inventors: Gregory A. Lazar, Gregory L. Moore
  • MODIFIED Fc MOLECULES
    Publication number: 20100249382
    Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
    Type: Application
    Filed: June 4, 2010
    Publication date: September 30, 2010
    Inventors: JOHN R. DESJARLAIS, SHER BAHADUR KARKI, GREGORY ALAN LAZAR, JOHN O. RICHARDS, GREGORY L. MOORE, DAVID F. CARMICHAEL
  • Method of treatment using adiponectin variants
    Patent number: 7749956
    Abstract: A method of treating a mammal with an adiponectin mediated disorder comprising administering a therapeutically effective amount of an adiponectin variant with at least a 3-fold increased solubility relative to residues 110-244 of human adiponectin.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: July 6, 2010
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Adiponectin variants
    Patent number: 7709607
    Abstract: An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: May 4, 2010
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Pharmaceutical compositions of adiponectin variants and methods of storage
    Patent number: 7678886
    Abstract: A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: March 16, 2010
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Methods for rational pegylation of proteins
    Patent number: 7610156
    Abstract: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: October 27, 2009
    Assignee: Xencor, Inc.
    Inventors: John R. Desjarlais, Jonathan Zalevsky, Gregory L. Moore
  • Globular adiponectin variants
    Patent number: 7592423
    Abstract: An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the adiponectin variant is not glycosylated, the adiponectin variant does not have residues 1-100 relative to human adiponectin, and wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: September 22, 2009
    Assignee: Xencor, Inc.
    Inventors: Jonathan Zalevsky, Duc-Hanh Thi Nguyen, Gregory L. Moore, Sergei A. Ezhevsky, John R. Desjarlais, Arthur J. Chirino, Darian Cash, Matthew J. Bernett
  • Methods and compositions for inhibiting CD32B expressing cells
    Publication number: 20090136485
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: May 30, 2008
    Publication date: May 28, 2009
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Optimized Fc variants
    Publication number: 20090042291
    Abstract: The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: May 30, 2008
    Publication date: February 12, 2009
    Applicant: Xencor, Inc.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • Fc variants with optimized Fc receptor binding properties
    Publication number: 20080206867
    Abstract: The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.
    Type: Application
    Filed: October 31, 2007
    Publication date: August 28, 2008
    Inventors: John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, John O. Richards, Gregory L. Moore, David F. Carmichael
  • Methods for the design of libraries of protein variants
    Publication number: 20080207467
    Abstract: The present invention is directed to designing a collection of protein variants.
    Type: Application
    Filed: September 7, 2006
    Publication date: August 28, 2008
    Inventors: Gregory L. Moore, John R. Desjarlais
  • Method for Rational Pegylation of Proteins
    Publication number: 20080113410
    Abstract: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.
    Type: Application
    Filed: October 30, 2007
    Publication date: May 15, 2008
    Applicant: Xencor, Inc.
    Inventors: John R. Desjarlais, Jonathan Zalevsky, Gregory L. Moore